These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8190919)

  • 21. Management of thalassemia major (Cooley's anemia).
    Piomelli S; Loew T
    Hematol Oncol Clin North Am; 1991 Jun; 5(3):557-69. PubMed ID: 1864823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of radiologic skeletal changes in thalassemia.
    Bedair EM; Helmy AN; Yakout K; Soliman AT
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():123-6. PubMed ID: 19337165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF; Peng CT; Wu KH; Tsai CH
    Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major.
    De Sanctis V; Katz M; Vullo C; Bagni B; Ughi M; Wonke B
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):791-8. PubMed ID: 8033371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular function in thalassemia major: protective effect of deferoxamine.
    Desideri A; Scattolin G; Gabellini A; Cavuto F; Vanzelli M; Formichi M; Corbara F
    Can J Cardiol; 1994; 10(1):93-6. PubMed ID: 8111676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeuetic management of patients with thalassemia major].
    Thuret I
    Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus infection and liver disease in children with thalassemia.
    Locasciulli A; Monguzzi W; Tornotti G; Bianco P; Masera G
    Bone Marrow Transplant; 1993; 12 Suppl 1():18-20. PubMed ID: 7690633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects].
    Piras V; Tuveri F; Dessì C; Pittau R; Origa R; Basile R; Muroni PP; Pittau A
    Minerva Stomatol; 2003 May; 52(5):241-6. PubMed ID: 12874543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
    Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
    Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High transfusion in children with beta-thalassemia/Hb E: clinical and laboratory assessment of 18 cases.
    Torcharus K; Withayathawornwong W; Sriphaisal T; Krutvacho T; Arnutti P; Suwanasophorn C
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():96-9. PubMed ID: 7886617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
    Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.